Improvement without impairment: A review of clinical data for quetiapine in the treatment of schizophrenia

Journal of Clinical Psychopharmacology

Volumn 23, Issue 3 SUPPL. 1, 2003, Pages

  Tandon, Rajiv ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; DRUG EFFICACY; DRUG TOLERABILITY; EMOTIONAL DISORDER; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; LONG TERM CARE; NEGATIVE SYNDROME; OUTCOMES RESEARCH; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; SYNDROME DELINEATION; TARDIVE DYSKINESIA; WEIGHT GAIN;

EID: 0038046546     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000084034.22282.78     Document Type: Conference Paper

References (18)

1. Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. US SEROQUEL Study Group. J Clin Psychopharmacol 1996;16:158-69.
2. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997;54:549-57.
3. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997;42:233-46.
4. Emsley RA, Raniwalla J, Bailey PJ, et al. A comparison of the effects of quetiapine ('Seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol 2000;15:121-31.
5. Copolov DL, Link CG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia. Psychol Med 2000;30:95-105.
6. Cutler AJ. Quetiapine effective in reducing anxiety: clinical evidence. In: Proceedings of the American Psychiatric Association Annual Meeting. May 5-10, New Orleans, Louisiana, 2001.
7. Velligan DI, Newcomer J, Pultz J, et al. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res 2002;53:239-48.
8. Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 2001;23:1839-54.
9. Meltzer HY, Dev VJ. Suicidality during quetiapine treatment: a risk-benefit assessment. In Proceedings of the 22nd Collegium Internationale Neuro-Psychopharmacologicum Congress. July 9-13, Brussels, Belgium, 2000.
10. Purdon SE, Malla A, Labelle A, et al. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 2001;26:137-49.
11. Kasper S. Maintenance of long-term efficacy and safety of quetiapine in the treatment of schizophrenia. In: Proceedings of the American College of Neuropsychopharmacology Annual Meeting. December 10-14, San Juan, Puerto Rico, 2000.
12. Kane J. Tardive dyskinesia: epidemiological and clinical presentation. In: Bloom F, Kupfer D, eds. Psychopharmacology: the Fourth Generation of Progress. New York: Raven Press, 1995:1485-95.
13. Glazer W, Morgenstern H, Pultz J, et al. Incidence of Persistent Tardive Dyskinesia May Be Lower with Quetiapine Treatment than Previously Reported with Typical Antipsychotics in Patients with Psychoses. Nashville: American College of Neuropsychopharmacology, 1999.
14. Brecher M, Rak I, Westhead E, et al. The long-term effect of quetiapine ('Seroquel') monotherapy on weight in patients with schizophrenia. Int J Psychiatry Clin Pract 2000;4:287-292.
15. Hamner MB, Arvanitis LA, Miller BG, et al. Plasma prolactin in schizophrenia subjects treated with Seroquel (ICI 204,636). Psychopharmacol Bull 1996;32:107-10.
16. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-18.
17. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158:765-74.
18. Tandon R, Jibson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 2003;28(Suppl 1):9-26.